Paratek Pharmaceuticals Competitors

Paratek Pharmaceuticals (NASDAQ:PRTK) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 7.7% of Paratek Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Paratek Pharmaceuticals and Johnson & Johnson's revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Paratek Pharmaceuticals and Johnson & Johnson, as reported by MarketBeat.

Paratek Pharmaceuticals currently has a consensus price target of $17.00, indicating a potential upside of 113.57%. Johnson & Johnson has a consensus price target of $180.6429, indicating a potential upside of 12.03%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Paratek Pharmaceuticals is more favorable than Johnson & Johnson.

Profitability

This table compares Paratek Pharmaceuticals and Johnson & Johnson's net margins, return on equity and return on assets.

Risk & Volatility

Paratek Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Summary

Johnson & Johnson beats Paratek Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Paratek Pharmaceuticals (NASDAQ:PRTK) and Pfizer (NYSE:PFE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.4% of Pfizer shares are owned by institutional investors. 7.7% of Paratek Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Paratek Pharmaceuticals and Pfizer's revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Paratek Pharmaceuticals and Pfizer, as reported by MarketBeat.

Paratek Pharmaceuticals currently has a consensus price target of $17.00, indicating a potential upside of 113.57%. Pfizer has a consensus price target of $38.5714, indicating a potential upside of 5.39%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Paratek Pharmaceuticals is more favorable than Pfizer.

Profitability

This table compares Paratek Pharmaceuticals and Pfizer's net margins, return on equity and return on assets.

Risk & Volatility

Paratek Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Summary

Pfizer beats Paratek Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Paratek Pharmaceuticals (NASDAQ:PRTK) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Profitability

This table compares Paratek Pharmaceuticals and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Paratek Pharmaceuticals and Merck & Co., Inc., as reported by MarketBeat.

Paratek Pharmaceuticals currently has a consensus price target of $17.00, indicating a potential upside of 113.57%. Merck & Co., Inc. has a consensus price target of $95.9167, indicating a potential upside of 25.69%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Paratek Pharmaceuticals is more favorable than Merck & Co., Inc..

Institutional & Insider Ownership

49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 7.7% of Paratek Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Paratek Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Earnings and Valuation

This table compares Paratek Pharmaceuticals and Merck & Co., Inc.'s revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Summary

Merck & Co., Inc. beats Paratek Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares AbbVie and Paratek Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AbbVie and Paratek Pharmaceuticals, as provided by MarketBeat.

AbbVie currently has a consensus target price of $115.75, indicating a potential upside of 7.63%. Paratek Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 113.57%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Paratek Pharmaceuticals is more favorable than AbbVie.

Institutional & Insider Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 7.7% of Paratek Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

AbbVie has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Valuation & Earnings

This table compares AbbVie and Paratek Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Paratek Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Eli Lilly and and Paratek Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Eli Lilly and and Paratek Pharmaceuticals, as provided by MarketBeat.

Eli Lilly and currently has a consensus target price of $196.40, indicating a potential upside of 6.46%. Paratek Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 113.57%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Paratek Pharmaceuticals is more favorable than Eli Lilly and.

Institutional & Insider Ownership

75.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by insiders. Comparatively, 7.7% of Paratek Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Eli Lilly and has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Valuation & Earnings

This table compares Eli Lilly and and Paratek Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Eli Lilly and has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Summary

Eli Lilly and beats Paratek Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Bristol-Myers Squibb and Paratek Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Bristol-Myers Squibb and Paratek Pharmaceuticals, as provided by MarketBeat.

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 19.22%. Paratek Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 113.57%. Given Paratek Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Paratek Pharmaceuticals is more favorable than Bristol-Myers Squibb.

Institutional & Insider Ownership

72.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 49.0% of Paratek Pharmaceuticals shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 7.7% of Paratek Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Bristol-Myers Squibb has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bristol-Myers Squibb and Paratek Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Paratek Pharmaceuticals on 9 of the 15 factors compared between the two stocks.